Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Launched by BIOSANTE PHARMACEUTICALS · Jan 30, 2008
Trial Information
Current as of June 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Must be between the ages of 30 to 65 years
- • Must have undergone hysterectomy and bilateral salpingo-oophorectomy
- Exclusion Criteria:
- • A history of allergic reactions to androgens (oral or patch), topical alcohol, or any component of the formulation
- • Any systemic skin diseases or local skin abnormalities in the area of application
- • Diagnosed with another primary female sexual dysfunction (e.g., Sexual Aversion Disorder, Female Sexual Arousal Disorder).
- • A medical condition that could affect or interfere with sexual function
- • Using a systemic topical gel or cream estrogen therapy.
About Biosante Pharmaceuticals
Biosante Pharmaceuticals is a biopharmaceutical company dedicated to the development of innovative therapeutics to address unmet medical needs in various therapeutic areas, including oncology, urology, and women's health. With a strong focus on advancing novel drug candidates through rigorous clinical trials, Biosante leverages its expertise in drug formulation and delivery technologies to enhance patient outcomes. The company's commitment to scientific excellence and collaboration with healthcare professionals positions it as a key player in the pharmaceutical industry, striving to improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Huntsville, Alabama, United States
Pinellas Park, Florida, United States
Edina, Minnesota, United States
Las Vegas, Nevada, United States
Akron, Ohio, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Eugene, Oregon, United States
Greer, South Carolina, United States
San Antonio, Texas, United States
Murray, Utah, United States
Mountlake Terrace, Washington, United States
Hoover, Alabama, United States
Glendale, Arizona, United States
Tucson, Arizona, United States
Hot Springs, Arkansas, United States
Buena Park, California, United States
San Diego, California, United States
Denver, Colorado, United States
Denver, Colorado, United States
Ridgefield, Connecticut, United States
Washington, District Of Columbia, United States
Miami, Florida, United States
St. Petersburg, Florida, United States
West Palm Beach, Florida, United States
Addison, Illinois, United States
Shreveport, Louisiana, United States
Baltimore, Maryland, United States
Detroit, Michigan, United States
Grand Rapids, Michigan, United States
Saginaw, Michigan, United States
St. Clair Shores, Michigan, United States
St. Paul, Minnesota, United States
Missoula, Montana, United States
Lincoln, Nebraska, United States
Poughkeepsie, New York, United States
Cary, North Carolina, United States
Charlotte, North Carolina, United States
Winston Salem, North Carolina, United States
Fargo, North Dakota, United States
Wexford, Pennsylvania, United States
Columbia, South Carolina, United States
Hilton Head Island, South Carolina, United States
Mount Pleasant, South Carolina, United States
Watertown, South Dakota, United States
Bristol, Tennessee, United States
Chattanooga, Tennessee, United States
Memphis, Tennessee, United States
Nashville, Tennessee, United States
Austin, Texas, United States
Corpus Christi, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Williston, Vermont, United States
Charlottesville, Virginia, United States
Norfolk, Virginia, United States
Richmond, Virginia, United States
Virginia Beach, Virginia, United States
Tacoma, Washington, United States
Sarnia, Ontario, Canada
Windsor, Ontario, Canada
Shawinigan, Quebec, Canada
Patients applied
Trial Officials
Michael C Snabes, MD, PhD
Study Director
BioSante Pharmaceuticals, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials